Latest News

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.

FDA gives full approval to selpercatinib for RET fusion solid tumors, backed by 47% response rate and long-lasting benefit across cancers.

Analyses of the CASSIOPEIA trial showed that some patients' outcomes could be associated with disease features besides depth of response alone.

Phase 3 China trial shows B7-H3 ADC risvutatug rezetecan extends survival vs topotecan in relapsed SCLC, signaling a promising new option.

During a live event, Sapna Patel, MD, and participants discussed second-line treatment selection for a patient with mucosal melanoma and considered how the limited available data shape that choice.

Dostarlimab previously received breakthrough therapy designation from the FDA for dMMR/MSI-H rectal cancer.

The FDA will review the CELMoD mezigdomide in combination with carfilzomib, and dexamethasone based on the SUCCESSOR-2 trial.

Patient-level analyses suggest DCVax-L boosts glioblastoma survival by up to 6 months, with peer review pending and no randomized control.

Flavonoid-rich foods like apples, oranges, and berries link to lower breast cancer risk, with the biggest benefit seen in women with high genetic risk.

This is the third complete response letter the FDA has issued for rivoceranib plus camrelizumab for hepatocellular carcinoma.

New study shows breast cancers within 3 years postpartum score higher on Oncotype DX, reshaping risk window and treatment decisions.

Rising out-of-pocket costs push more adults to skip needed care, regardless of cancer history—highlighting financial toxicity and the need for smarter risk screening.

KEYNOTE-355 suggests responders can pause chemo yet maintain survival on pembrolizumab; immune side effects are mostly mild and manageable.

A phase 1 study of actinium (²²⁵Ac) rhPSMA-10.1 injection in patients who have received prior lutetium-177 PSMA-targeted therapy has initiated dosing of patients with metastatic castration-resistant prostate cancer.

TRIPLEX finds thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival.

FDA clears perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, boosting event-free and overall survival ahead of cystectomy.

SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.

The FDA approval was based on studies using an on-body injector to administer isatuximab easily.

Pegfilgrastim-pccg now carries the same indications as its reference product, Neulasta.

During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

FDA clears IND for UGN-501 oncolytic virus, launching phase 1 NMIBC trial to test intravesical safety and immune-driven tumor control.

LAURA trial safety update shows osimertinib after chemoradiotherapy in stage III EGFR-mutant NSCLC stays manageable, no new signals.

The PTEN IHC CDx is a companion diagnostic approved by the FDA to determine patients' eligibility for capivasertib in metastatic prostate cancer.

Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated NSCLC in phase 2 THIO-101 trial interim data (NCT05208944).

The FDA set a PDUFA date of April 28, 2027 for approval of the gamma secretase inhibitor for progressing desmoid tumors.

In an interview, Melody Chang, RPh, MBA, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

During a live event, Bruna Pellini, MD, and participants discussed treatment sequencing and post progression management in patients with ROS1-positive advanced non–small cell lung cancer.